>>Signaling Pathways>> GPCR/G protein>> Angiotensin Receptor>>Irbesartan-d4

Irbesartan-d4

Catalog No.GC40208

Irbesartan D4는 Irbesartan으로 표시된 중수소이며, 이는 매우 강력하고 특이적인 안지오텐신 II 유형 1(AT1) 수용체 길항제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Irbesartan-d4 Chemical Structure

Cas No.: 1216883-23-6

Size 가격 재고 수량
500μg
US$188.00
재고 있음
1mg
US$357.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Irbesartan-d4 is intended for use as an internal standard for the quantification of irbesartan by GC- or LC-MS. Irbesartan is an antagonist of the angiotensin II type 1 (AT1) receptor (Ki = 1.3 nM). It is an insurmountable antagonist of AT1, as its antagonism cannot be overcome by increasing concentrations of angiotensin II. Irbesartan (3, 10, and 30 mg/kg) reduces blood pressure in stroke-prone spontaneously hypertensive rats and increases survival of SPSH rats fed a high-salt low-protein diet. It also reduces plaque formation, collagen content, as well as the increased expression of the AT1 receptor, PDGF-b, MCP-1, and VCAM-1 in a model of diabetes-induced atherosclerosis using apolipoprotein E (ApoE) knockout mice with diabetes induced by streptozotocin . Formulations containing irbesartan have been used, alone and in combination with diuretics, in the treatment of hypertension.

리뷰

Review for Irbesartan-d4

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Irbesartan-d4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.